Envyapple的个人主页 - 老虎社区

Envyapple

Envyapple

暂无个人介绍

IP属地：未知

422关注

13粉丝

0主题

0勋章

2021-11-22

Yes

抱歉，原内容已删除

2021-11-18

$S&P500 ETF(SPY)$[What]

2021-11-14

Yes

Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.

2021-11-11

$MasterCard(MA)$[Cool]

2021-11-10

$NXP Semiconductors NV(NXPI)$[Cool]

2021-11-09

$Moderna, Inc.(MRNA)$Come come up up 🆙

2021-11-08

$Alibaba(BABA)$[Cool]

2021-11-08

$Alibaba(BABA)$[Cool]

2021-11-07

$Meta Platforms, Inc.(FB)$[Cool]

2021-11-07

$Moderna, Inc.(MRNA)$[Spurting]

2021-11-06

$Alibaba(BABA)$[Spurting]

2021-11-06

$Moderna, Inc.(MRNA)$[Cry]

2021-11-05

$Qualcomm(QCOM)$[Miser]

2021-11-04

$Qualcomm(QCOM)$[Miser]

2021-11-03

$Consumer Discretionary Select Sector SPDR Fund(XLY)$[What]

2021-11-03

$Meta Platforms, Inc.(FB)$come

2021-11-02

$Micron Technology(MU)$加油

2021-11-02

$Meta Platforms, Inc.(FB)$see light

2021-11-01

$Amazon.com(AMZN)$I [Miser]

2021-11-01

$The Communication Services Select Sector SPDR Fund(XLC)$[Miser]

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3580175323096207,"uuid":"3580175323096207","gmtCreate":1619060402558,"gmtModify":1628657908276,"name":"Envyapple","pinyin":"envyapple","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":13,"headSize":422,"tweetSize":244,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.53%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"02aa7f16703b4ce4ace6f1a7665789cc-1","templateUuid":"02aa7f16703b4ce4ace6f1a7665789cc","name":"知识体验官","description":"观看学堂课程满5节","bigImgUrl":"https://static.tigerbbs.com/fb5ae275631fb96a92d475cdc85d2302","smallImgUrl":"https://static.tigerbbs.com/c2660a1935bd2105e97c9915619936c3","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.61%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":6,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":872548490,"gmtCreate":1637552135595,"gmtModify":1637552135673,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Yes&nbsp;","listText":"Yes&nbsp;","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872548490","repostId":"2184782893","repostType":2,"isVote":1,"tweetType":1,"viewCount":858,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878497503,"gmtCreate":1637217338555,"gmtModify":1637217338722,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SPY\">$S&amp;P500 ETF(SPY)$</a>[What]&nbsp;","listText":"<a href=\"https://laohu8.com/S/SPY\">$S&amp;P500 ETF(SPY)$</a>[What]&nbsp;","text":"$S&P500 ETF(SPY)$[What]","images":[{"img":"https://static.tigerbbs.com/b83b77dfe7a70c61f33c3cafbaf4d2a1","width":"1125","height":"3125"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878497503","isVote":1,"tweetType":1,"viewCount":870,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":873371276,"gmtCreate":1636867660258,"gmtModify":1636867660394,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873371276","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1},"isVote":1,"tweetType":1,"viewCount":489,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870138111,"gmtCreate":1636592344194,"gmtModify":1636592344297,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MA\">$MasterCard(MA)$</a>[Cool]&nbsp;","listText":"<a href=\"https://laohu8.com/S/MA\">$MasterCard(MA)$</a>[Cool]&nbsp;","text":"$MasterCard(MA)$[Cool]","images":[{"img":"https://static.tigerbbs.com/b4f59ec12c151b2ad83983f97f6a5a2f","width":"1242","height":"1968"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870138111","isVote":1,"tweetType":1,"viewCount":762,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":847642983,"gmtCreate":1636517772550,"gmtModify":1636517772826,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NXPI\">$NXP Semiconductors NV(NXPI)$</a>[Cool]&nbsp;","listText":"<a href=\"https://laohu8.com/S/NXPI\">$NXP Semiconductors NV(NXPI)$</a>[Cool]&nbsp;","text":"$NXP Semiconductors NV(NXPI)$[Cool]","images":[{"img":"https://static.tigerbbs.com/4e62edf73fe39fe5f972b979658eeafd","width":"1125","height":"3507"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847642983","isVote":1,"tweetType":1,"viewCount":606,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":844857544,"gmtCreate":1636418648922,"gmtModify":1636418649186,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Come come up up 🆙&nbsp;","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Come come up up 🆙&nbsp;","text":"$Moderna, Inc.(MRNA)$Come come up up 🆙","images":[{"img":"https://static.tigerbbs.com/c9d64a4e8780c0e5a8ad38a4626fe414","width":"1242","height":"1968"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844857544","isVote":1,"tweetType":1,"viewCount":654,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":845402211,"gmtCreate":1636357436261,"gmtModify":1636357436525,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>[Cool]&nbsp;","listText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>[Cool]&nbsp;","text":"$Alibaba(BABA)$[Cool]","images":[{"img":"https://static.tigerbbs.com/5a153e8a41147b2027159048ec0c39e0","width":"1125","height":"3670"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845402211","isVote":1,"tweetType":1,"viewCount":815,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":845406269,"gmtCreate":1636357354670,"gmtModify":1636357354898,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>[Cool]&nbsp;","listText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>[Cool]&nbsp;","text":"$Alibaba(BABA)$[Cool]","images":[{"img":"https://static.tigerbbs.com/5504abba64c50af2a77fc4f176c6c653","width":"1242","height":"1968"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845406269","isVote":1,"tweetType":1,"viewCount":592,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":842783802,"gmtCreate":1636244608002,"gmtModify":1636244608874,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FB\">$Meta Platforms, Inc.(FB)$</a>[Cool]&nbsp;","listText":"<a href=\"https://laohu8.com/S/FB\">$Meta Platforms, Inc.(FB)$</a>[Cool]&nbsp;","text":"$Meta Platforms, Inc.(FB)$[Cool]","images":[{"img":"https://static.tigerbbs.com/68c32cfcb72ec421c8d35d73b9ec35fa","width":"1125","height":"3670"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842783802","isVote":1,"tweetType":1,"viewCount":536,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":842789485,"gmtCreate":1636244578598,"gmtModify":1636244578824,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>[Spurting]&nbsp;","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>[Spurting]&nbsp;","text":"$Moderna, Inc.(MRNA)$[Spurting]","images":[{"img":"https://static.tigerbbs.com/28973fe24239e54b3a55e59eb3a123d5","width":"1242","height":"1968"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842789485","isVote":1,"tweetType":1,"viewCount":541,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":842141777,"gmtCreate":1636158350253,"gmtModify":1636158350477,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>[Spurting]&nbsp;","listText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>[Spurting]&nbsp;","text":"$Alibaba(BABA)$[Spurting]","images":[{"img":"https://static.tigerbbs.com/8a94031a1afcf7cd28d3410d854f4c87","width":"1125","height":"3670"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842141777","isVote":1,"tweetType":1,"viewCount":169,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":842141818,"gmtCreate":1636158315466,"gmtModify":1636158321613,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>[Cry]&nbsp;","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>[Cry]&nbsp;","text":"$Moderna, Inc.(MRNA)$[Cry]","images":[{"img":"https://static.tigerbbs.com/28973fe24239e54b3a55e59eb3a123d5","width":"1242","height":"1968"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/842141818","isVote":1,"tweetType":1,"viewCount":245,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":846626037,"gmtCreate":1636079363982,"gmtModify":1636079929660,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/QCOM\">$Qualcomm(QCOM)$</a>[Miser]&nbsp;","listText":"<a href=\"https://laohu8.com/S/QCOM\">$Qualcomm(QCOM)$</a>[Miser]&nbsp;","text":"$Qualcomm(QCOM)$[Miser]","images":[{"img":"https://static.tigerbbs.com/34443c2b9c1a77e301b622350f95d986","width":"1125","height":"3751"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846626037","isVote":1,"tweetType":1,"viewCount":357,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":848156327,"gmtCreate":1635985192584,"gmtModify":1635985192855,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/QCOM\">$Qualcomm(QCOM)$</a>[Miser]&nbsp;","listText":"<a href=\"https://laohu8.com/S/QCOM\">$Qualcomm(QCOM)$</a>[Miser]&nbsp;","text":"$Qualcomm(QCOM)$[Miser]","images":[{"img":"https://static.tigerbbs.com/4f3941d4275c0c3b1741ca4decf6c318","width":"1125","height":"3507"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848156327","isVote":1,"tweetType":1,"viewCount":323,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":841887284,"gmtCreate":1635901597045,"gmtModify":1635901597133,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XLY\">$Consumer Discretionary Select Sector SPDR Fund(XLY)$</a>[What]&nbsp;","listText":"<a href=\"https://laohu8.com/S/XLY\">$Consumer Discretionary Select Sector SPDR Fund(XLY)$</a>[What]&nbsp;","text":"$Consumer Discretionary Select Sector SPDR Fund(XLY)$[What]","images":[{"img":"https://static.tigerbbs.com/4d98a477c191d88f8fb06993895573d8","width":"1125","height":"3297"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841887284","isVote":1,"tweetType":1,"viewCount":271,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":841887055,"gmtCreate":1635901552550,"gmtModify":1635901552670,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FB\">$Meta Platforms, Inc.(FB)$</a>come","listText":"<a href=\"https://laohu8.com/S/FB\">$Meta Platforms, Inc.(FB)$</a>come","text":"$Meta Platforms, Inc.(FB)$come","images":[{"img":"https://static.tigerbbs.com/b9615f92b0f2ce95f52747cd056240af","width":"1242","height":"1968"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841887055","isVote":1,"tweetType":1,"viewCount":542,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":843146472,"gmtCreate":1635814944788,"gmtModify":1635814945264,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MU\">$Micron Technology(MU)$</a>加油","listText":"<a href=\"https://laohu8.com/S/MU\">$Micron Technology(MU)$</a>加油","text":"$Micron Technology(MU)$加油","images":[{"img":"https://static.tigerbbs.com/0f1be8441b1047aa3ea21839818e8388","width":"1242","height":"1968"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843146472","isVote":1,"tweetType":1,"viewCount":296,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":843148872,"gmtCreate":1635814917642,"gmtModify":1635814917717,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FB\">$Meta Platforms, Inc.(FB)$</a>see light","listText":"<a href=\"https://laohu8.com/S/FB\">$Meta Platforms, Inc.(FB)$</a>see light","text":"$Meta Platforms, Inc.(FB)$see light","images":[{"img":"https://static.tigerbbs.com/2874ebf3a7f00ed0d23e79c85a9ac30c","width":"1125","height":"3425"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843148872","isVote":1,"tweetType":1,"viewCount":252,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":849105036,"gmtCreate":1635732572767,"gmtModify":1635732572869,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMZN\">$Amazon.com(AMZN)$</a>I [Miser]&nbsp;","listText":"<a href=\"https://laohu8.com/S/AMZN\">$Amazon.com(AMZN)$</a>I [Miser]&nbsp;","text":"$Amazon.com(AMZN)$I [Miser]","images":[{"img":"https://static.tigerbbs.com/cf0742c2cbe540323e50486b2ade77f8","width":"1242","height":"1968"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849105036","isVote":1,"tweetType":1,"viewCount":221,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":849102371,"gmtCreate":1635732549610,"gmtModify":1635732549732,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XLC\">$The Communication Services Select Sector SPDR Fund(XLC)$</a>[Miser]&nbsp;","listText":"<a href=\"https://laohu8.com/S/XLC\">$The Communication Services Select Sector SPDR Fund(XLC)$</a>[Miser]&nbsp;","text":"$The Communication Services Select Sector SPDR Fund(XLC)$[Miser]","images":[{"img":"https://static.tigerbbs.com/c9b32dbb5e9f99be3be976cb40272517","width":"1125","height":"3460"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849102371","isVote":1,"tweetType":1,"viewCount":396,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"hots":[{"id":853105724,"gmtCreate":1634777813157,"gmtModify":1634777837694,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>[What]&nbsp;","listText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>[What]&nbsp;","text":"$Alibaba(BABA)$[What]","images":[{"img":"https://static.tigerbbs.com/c8447f87f6e3341a32062e6b650a8c07","width":"1125","height":"3588"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":1,"link":"https://laohu8.com/post/853105724","isVote":1,"tweetType":1,"viewCount":99,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":873371276,"gmtCreate":1636867660258,"gmtModify":1636867660394,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873371276","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1},"isVote":1,"tweetType":1,"viewCount":489,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827236119,"gmtCreate":1634475653549,"gmtModify":1634475653810,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Yes&nbsp;","listText":"Yes&nbsp;","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/827236119","repostId":"1132582737","repostType":4,"repost":{"id":"1132582737","pubTimestamp":1634311475,"share":"https://www.laohu8.com/m/news/1132582737?lang=&edition=full","pubTime":"2021-10-15 23:24","market":"us","language":"en","title":"JPMorgan On Amazon Stock: 29% Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1132582737","media":"TheStreet","summary":"Amazon stock has fallen victim of its own success: shares of the e-commerce giant have lagged the S&","content":"<p>Amazon stock has fallen victim of its own success: shares of the e-commerce giant have lagged the S&amp;P 500 since its disappointing Q2 earnings day. But JPMorgan is optimistic and sees upside ahead.</p>\n<p>Since the release of Amazon’s most recent earnings report, investors have watched shares of the cloud and e-commerce giant tank by 11%. Amazon stock&nbsp;underperformed an already weak S&amp;P 500 by three percentage points over the period, leaving some to question: is AMZN still a good investment?</p>\n<p>According to experts at JPMorgan (JPM), the answer is yes. Today, the Amazon Maven presents the main reasons why five-star&nbsp;rated&nbsp;analyst Doug Anmuth believes that Amazon stock is about to surge, producing an estimated 29% in gains through 2022.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8c8e5f4ca5aa3dba7bef61858521bd17\" tg-width=\"1240\" tg-height=\"827\" width=\"100%\" height=\"auto\"><span>Figure 1: J.P. Morgan offices in Hong Kong.</span></p>\n<p><b>Getting back on track</b></p>\n<p>As the&nbsp;Amazon Maven mentioned&nbsp;recently, the impact of the pandemic on shopping habits led analysts to overestimate Amazon’s revenues for the current year. This is the very first reason why JPMorgan&nbsp;believes&nbsp;that AMZN will get a green light to climb again: “[the stock is heading] closer to the last quarter of difficult COVID-19 comps in the first quarter of 2022\", which should help to reset sentiment.</p>\n<p>Once 2020 results are left in the rearview mirror, the e-commerce company will face more realistic, non-pandemic-inflated projections. As mentioned by Mr. Anmuth himself, \"further downward revisions to 2022 profit estimates would help lower the bar and potentially create more of a clearing event”.</p>\n<p><b>Holiday upside</b></p>\n<p>Another reason why Mr. Anmuth believes Amazon stock will head higher is the beginning of the holiday season. Since the market has been so cautious towards AMZN lately, the stock has been trading at lower multiples than would otherwise be considered reasonable. The holidays, on the other hand, could be the bullish catalyst that investors need to own the stock again.</p>\n<p>Lastly, there is the potential for an increase in Prime subscription price in 2022. Considering an estimated 150 million US Prime members in 2021, a $20 dollar hike in annual fee would lead to an extra $3 billion heading towards Amazon’s coffers.</p>\n<p>At first glance, the figure may not seem like much, given Amazon’s revenues of $380 billion in 2020. However, keep in mind that nearly all the price increase would flow cleanly into Amazon’s operating income. On a 2020 basis, this would represent growth of nearly 15% in pre-tax profits.</p>\n<p><b>What do other experts say?</b></p>\n<p>Other reports published recently also support the bullish thesis. Mark Mahaney from Evercore ISI&nbsp;talked&nbsp;to 15 industry experts, including former Amazon employees, during the research firm’s Amazon Day Symposium. The analyst liked what he saw and issued a hefty $4,700 target price.</p>\n<p>Wolfe Research’s Deepak Mathivanan, on the other hand,lowered&nbsp;his price target on AMZN modestly to $3,850 from $3,900, despite maintaining an outperform rating. Sitting closer to the consensus price target is Goldman Sachs’ Eric Sheridan, who is bullish and&nbsp;believes&nbsp;that AMZN shares are worth $4,250.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JPMorgan On Amazon Stock: 29% Upside Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJPMorgan On Amazon Stock: 29% Upside Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-15 23:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/amazon/news/jpmorgan-on-amazon-stock-29-upside-potential><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amazon stock has fallen victim of its own success: shares of the e-commerce giant have lagged the S&P 500 since its disappointing Q2 earnings day. But JPMorgan is optimistic and sees upside ahead.\n...</p>\n\n<a href=\"https://www.thestreet.com/amazon/news/jpmorgan-on-amazon-stock-29-upside-potential\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"source_url":"https://www.thestreet.com/amazon/news/jpmorgan-on-amazon-stock-29-upside-potential","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1132582737","content_text":"Amazon stock has fallen victim of its own success: shares of the e-commerce giant have lagged the S&P 500 since its disappointing Q2 earnings day. But JPMorgan is optimistic and sees upside ahead.\nSince the release of Amazon’s most recent earnings report, investors have watched shares of the cloud and e-commerce giant tank by 11%. Amazon stock underperformed an already weak S&P 500 by three percentage points over the period, leaving some to question: is AMZN still a good investment?\nAccording to experts at JPMorgan (JPM), the answer is yes. Today, the Amazon Maven presents the main reasons why five-star rated analyst Doug Anmuth believes that Amazon stock is about to surge, producing an estimated 29% in gains through 2022.\nFigure 1: J.P. Morgan offices in Hong Kong.\nGetting back on track\nAs the Amazon Maven mentioned recently, the impact of the pandemic on shopping habits led analysts to overestimate Amazon’s revenues for the current year. This is the very first reason why JPMorgan believes that AMZN will get a green light to climb again: “[the stock is heading] closer to the last quarter of difficult COVID-19 comps in the first quarter of 2022\", which should help to reset sentiment.\nOnce 2020 results are left in the rearview mirror, the e-commerce company will face more realistic, non-pandemic-inflated projections. As mentioned by Mr. Anmuth himself, \"further downward revisions to 2022 profit estimates would help lower the bar and potentially create more of a clearing event”.\nHoliday upside\nAnother reason why Mr. Anmuth believes Amazon stock will head higher is the beginning of the holiday season. Since the market has been so cautious towards AMZN lately, the stock has been trading at lower multiples than would otherwise be considered reasonable. The holidays, on the other hand, could be the bullish catalyst that investors need to own the stock again.\nLastly, there is the potential for an increase in Prime subscription price in 2022. Considering an estimated 150 million US Prime members in 2021, a $20 dollar hike in annual fee would lead to an extra $3 billion heading towards Amazon’s coffers.\nAt first glance, the figure may not seem like much, given Amazon’s revenues of $380 billion in 2020. However, keep in mind that nearly all the price increase would flow cleanly into Amazon’s operating income. On a 2020 basis, this would represent growth of nearly 15% in pre-tax profits.\nWhat do other experts say?\nOther reports published recently also support the bullish thesis. Mark Mahaney from Evercore ISI talked to 15 industry experts, including former Amazon employees, during the research firm’s Amazon Day Symposium. The analyst liked what he saw and issued a hefty $4,700 target price.\nWolfe Research’s Deepak Mathivanan, on the other hand,lowered his price target on AMZN modestly to $3,850 from $3,900, despite maintaining an outperform rating. Sitting closer to the consensus price target is Goldman Sachs’ Eric Sheridan, who is bullish and believes that AMZN shares are worth $4,250.","news_type":1},"isVote":1,"tweetType":1,"viewCount":142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872548490,"gmtCreate":1637552135595,"gmtModify":1637552135673,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Yes&nbsp;","listText":"Yes&nbsp;","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872548490","repostId":"2184782893","repostType":2,"repost":{"id":"2184782893","pubTimestamp":1637464884,"share":"https://www.laohu8.com/m/news/2184782893?lang=&edition=full","pubTime":"2021-11-21 11:21","market":"us","language":"en","title":"3 Top Chip Stocks Ready for Bull Runs","url":"https://stock-news.laohu8.com/highlight/detail?id=2184782893","media":"Motley Fool","summary":"ASML, UMC, and Micron could all still have a lot of upside potential.","content":"<p>The global chip shortage has been generating strong tailwinds for the semiconductor sector over the past year. However, it might be difficult for investors to separate the winners from the losers if they don't understand how the semiconductor supply chain works.</p>\n<p>Today, I'll highlight three chip stocks that operate in very different parts of the semiconductor market, why they're all growing, and why they could still generate even bigger returns next year.</p>\n<h2>1. ASML</h2>\n<p><b>ASML Holding</b> (NASDAQ:ASML) is a Dutch semiconductor equipment maker. It's the world's largest manufacturer of lithography machines, which are used to etch circuit patterns onto silicon wafers. It's also the only manufacturer of high-end extreme ultraviolet (EUV) lithography machines, which are required to manufacture the world's smallest chips.</p>\n<p>The world's most advanced chip foundries -- including <b>Taiwan Semiconductor Manufacturing</b> (NYSE:TSM), <b>Samsung</b>, and <b>Intel</b> (NASDAQ:INTC) -- all use ASML's EUV machines, which cost about $150,000 each and require several planes to ship. ASML's dominance of this crucial chipmaking technology, which it refined over the past three decades, makes it a linchpin of the global semiconductor market.</p>\n<p>ASML's revenue rose 8% in 2019 and 18% in 2020, and it anticipates about 35% growth this year. It's selling EUV systems as rapidly as it can produce them, and a growing mix of those higher-margin devices boosted its gross margin from 44.7% in 2019 to 52.2% in the first nine months of 2021.</p>\n<p>ASML's stock price has more than doubled over the past 12 months, and it isn't cheap at 45 times forward earnings. However, this stock could still have plenty of upside potential as the chip shortage drags on -- since it will be impossible to resolve the crisis without buying significantly more machines from ASML.</p>\n<h2>2. UMC</h2>\n<p>ASML's top client is TSMC, the world's largest contract chipmaker and another linchpin of the semiconductor market. However, TSMC's smaller rival <b>United Microelectronics</b> (NYSE:UMC) is a more underrated play on the same trend.</p>\n<p>Unlike TSMC -- which manufactures the world's smallest chips for fabless chipmakers like <b>Advanced Micro Devices</b> and<b> Apple</b> -- UMC primarily manufactures older, larger, and cheaper chips for cars, Internet of Things (IoT) devices, and other gadgets.</p>\n<p>These chips aren't as powerful as TSMC's top-tier chips, but they're arguably just as essential. UMC's plants are already operating at their maximum capacities, but the company faces less pressure to aggressively upgrade its plants than TSMC, Samsung, or Intel, which are all engaged in the costly \"process race\" to manufacture smaller and more advanced chips.</p>\n<p>UMC ranks a distant third in the foundry market behind TSMC and Samsung, but it still generates impressive growth: Its revenue rose 4% in 2019 and jumped 25% in 2020, and analysts expect 18% growth this year.</p>\n<p>UMC's stock has more than doubled over the past 12 months, but it still looks reasonably valued at 22 times forward earnings. Like ASML, UMC will continue to profit from the chip shortage. Moreover, the traffic jam at TSMC and other top foundries could eventually divert more lower-end orders to UMC.</p>\n<h2>3. Micron</h2>\n<p>Lastly, I believe <b>Micron Technology </b>(NASDAQ:MU) -- <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the world's leading producers of DRAM and NAND memory chips -- is currently undervalued at eight times forward earnings. Micron's stock has risen nearly 30% over the past 12 months, but it's stalled out in recent months amid fears of a cyclical slowdown.</p>\n<p>Micron's revenue fell 8% in fiscal 2020 (which ended last September) as a global glut of memory chips caused market prices to plunge. But in fiscal 2021, its revenue rose 29% as those supplies and prices stabilized.</p>\n<p>Micron wasn't directly affected by the chip shortage, since it manufactures its own chips instead of outsourcing them to third-party foundries. However, it expects shortages of other PC components -- including CPUs and GPUs -- to indirectly curb the market's near-term demand for its memory chips. That warning, along with a softer-than-expected forecast for the first quarter, spooked investors last month.</p>\n<p>Nonetheless, analysts still expect Micron's revenue and earnings to rise 15% and 44%, respectively, this year, as it benefits from the secular expansion of the gaming, data center, cloud, 5G, and automotive markets. Those catalysts might also spark a \"super cycle\" in memory chip upgrades, which could last much longer than previous cycles and propel Micron's stock to fresh highs next year.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Top Chip Stocks Ready for Bull Runs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Top Chip Stocks Ready for Bull Runs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-21 11:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/20/3-top-chip-stocks-ready-for-a-bull-run/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The global chip shortage has been generating strong tailwinds for the semiconductor sector over the past year. However, it might be difficult for investors to separate the winners from the losers if ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/20/3-top-chip-stocks-ready-for-a-bull-run/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4554":"元宇宙及AR概念","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓","03145":"华夏亚洲高息股","BK4534":"瑞士信贷持仓","BK4147":"半导体设备","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4527":"明星科技股","BK4141":"半导体产品","BK4550":"红杉资本持仓","BK4526":"热门中概股","UMC":"联电","BK4503":"景林资产持仓","TSM":"台积电","BK4505":"高瓴资本持仓","ASML":"阿斯麦","BK4512":"苹果概念","BK4548":"巴美列捷福持仓","BK4529":"IDC概念","MU":"美光科技","03165":"华夏欧优股对冲","INTC":"英特尔"},"source_url":"https://www.fool.com/investing/2021/11/20/3-top-chip-stocks-ready-for-a-bull-run/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2184782893","content_text":"The global chip shortage has been generating strong tailwinds for the semiconductor sector over the past year. However, it might be difficult for investors to separate the winners from the losers if they don't understand how the semiconductor supply chain works.\nToday, I'll highlight three chip stocks that operate in very different parts of the semiconductor market, why they're all growing, and why they could still generate even bigger returns next year.\n1. ASML\nASML Holding (NASDAQ:ASML) is a Dutch semiconductor equipment maker. It's the world's largest manufacturer of lithography machines, which are used to etch circuit patterns onto silicon wafers. It's also the only manufacturer of high-end extreme ultraviolet (EUV) lithography machines, which are required to manufacture the world's smallest chips.\nThe world's most advanced chip foundries -- including Taiwan Semiconductor Manufacturing (NYSE:TSM), Samsung, and Intel (NASDAQ:INTC) -- all use ASML's EUV machines, which cost about $150,000 each and require several planes to ship. ASML's dominance of this crucial chipmaking technology, which it refined over the past three decades, makes it a linchpin of the global semiconductor market.\nASML's revenue rose 8% in 2019 and 18% in 2020, and it anticipates about 35% growth this year. It's selling EUV systems as rapidly as it can produce them, and a growing mix of those higher-margin devices boosted its gross margin from 44.7% in 2019 to 52.2% in the first nine months of 2021.\nASML's stock price has more than doubled over the past 12 months, and it isn't cheap at 45 times forward earnings. However, this stock could still have plenty of upside potential as the chip shortage drags on -- since it will be impossible to resolve the crisis without buying significantly more machines from ASML.\n2. UMC\nASML's top client is TSMC, the world's largest contract chipmaker and another linchpin of the semiconductor market. However, TSMC's smaller rival United Microelectronics (NYSE:UMC) is a more underrated play on the same trend.\nUnlike TSMC -- which manufactures the world's smallest chips for fabless chipmakers like Advanced Micro Devices and Apple -- UMC primarily manufactures older, larger, and cheaper chips for cars, Internet of Things (IoT) devices, and other gadgets.\nThese chips aren't as powerful as TSMC's top-tier chips, but they're arguably just as essential. UMC's plants are already operating at their maximum capacities, but the company faces less pressure to aggressively upgrade its plants than TSMC, Samsung, or Intel, which are all engaged in the costly \"process race\" to manufacture smaller and more advanced chips.\nUMC ranks a distant third in the foundry market behind TSMC and Samsung, but it still generates impressive growth: Its revenue rose 4% in 2019 and jumped 25% in 2020, and analysts expect 18% growth this year.\nUMC's stock has more than doubled over the past 12 months, but it still looks reasonably valued at 22 times forward earnings. Like ASML, UMC will continue to profit from the chip shortage. Moreover, the traffic jam at TSMC and other top foundries could eventually divert more lower-end orders to UMC.\n3. Micron\nLastly, I believe Micron Technology (NASDAQ:MU) -- one of the world's leading producers of DRAM and NAND memory chips -- is currently undervalued at eight times forward earnings. Micron's stock has risen nearly 30% over the past 12 months, but it's stalled out in recent months amid fears of a cyclical slowdown.\nMicron's revenue fell 8% in fiscal 2020 (which ended last September) as a global glut of memory chips caused market prices to plunge. But in fiscal 2021, its revenue rose 29% as those supplies and prices stabilized.\nMicron wasn't directly affected by the chip shortage, since it manufactures its own chips instead of outsourcing them to third-party foundries. However, it expects shortages of other PC components -- including CPUs and GPUs -- to indirectly curb the market's near-term demand for its memory chips. That warning, along with a softer-than-expected forecast for the first quarter, spooked investors last month.\nNonetheless, analysts still expect Micron's revenue and earnings to rise 15% and 44%, respectively, this year, as it benefits from the secular expansion of the gaming, data center, cloud, 5G, and automotive markets. Those catalysts might also spark a \"super cycle\" in memory chip upgrades, which could last much longer than previous cycles and propel Micron's stock to fresh highs next year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":858,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854421944,"gmtCreate":1635475045212,"gmtModify":1635475048193,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FB\">$Facebook(FB)$</a>[What]&nbsp;","listText":"<a href=\"https://laohu8.com/S/FB\">$Facebook(FB)$</a>[What]&nbsp;","text":"$Facebook(FB)$[What]","images":[{"img":"https://static.tigerbbs.com/53b6c9977535171fdd752734fe4e5d98","width":"1242","height":"1968"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/854421944","isVote":1,"tweetType":1,"viewCount":5,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":865661005,"gmtCreate":1632976676942,"gmtModify":1632976693454,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Goid","listText":"Goid","text":"Goid","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/865661005","repostId":"2171986054","repostType":4,"repost":{"id":"2171986054","pubTimestamp":1632973200,"share":"https://www.laohu8.com/m/news/2171986054?lang=&edition=full","pubTime":"2021-09-30 11:40","market":"us","language":"en","title":"3 Vanguard ETFs I'm Buying if the Stock Market Crashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2171986054","media":"Motley Fool","summary":"Nobody knows whether the market will crash. But if it does, I'm stocking up on these investments.","content":"<blockquote>\n <b>Nobody knows whether the market will crash. But if it does, I'm stocking up on these investments.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>The Vanguard S&amp;P 500 ETF can be a great option for withstanding market volatility.</li>\n <li>The Vanguard Total Stock Market ETF can help reduce your risk.</li>\n <li>The Vanguard Growth ETF can supercharge your investments.</li>\n</ul>\n<p>Over the past year and a half, the stock market has experienced <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the greatest growth streaks in history. The <b>S&amp;P 500</b> is up nearly 100% since March 2020, and investors have seen their portfolios skyrocket during that time.</p>\n<p>Some experts believe, however, that it's only a matter of time before prices fall. Market downturns may be intimidating, but they're normal. In fact, it's healthy for the market to experience corrections every so often, because stock prices can't continue climbing forever.</p>\n<p>Nobody knows for sure whether a crash is on the horizon, or, if it does happen, how significant it will be. However, if the market does take a turn for the worse, there are a few exchange-traded funds (ETFs) I'll be buying.</p>\n<p><img src=\"https://static.tigerbbs.com/9c5cb96961b54db9d77a960894b88df7\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>1. Vanguard S&amp;P 500 ETF (VOO)</h3>\n<p>It may seem counterintuitive to buy when the market is down, but crashes can be a fantastic opportunity to invest when prices are lower. ETFs trade like stocks, so when the market is down, their share prices are typically lower as well.</p>\n<p>One ETF I'm planning to invest in heavily if the market crashes is the <b>Vanguard S&amp;P 500 ETF</b> (NYSEMKT:VOO). Like its name suggests, this fund tracks the S&amp;P 500 and includes all the stocks within the index itself.</p>\n<p>The S&amp;P 500 ETF is one of the most dependable investments out there. Historically, the index itself has faced countless crashes and corrections, and it has recovered from each and every one. If the market crashes again, there's a very good chance this ETF will be able to bounce back. And by buying when prices are lower, you'll reap the rewards once the market recovers and prices increase once again.</p>\n<h3>2. Vanguard Total Stock Market ETF (VTI)</h3>\n<p>The <b>Vanguard Total Stock Market ETF</b> (NYSEMKT:VTI) is similar to the S&amp;P 500 ETF, but it includes more stocks from more diverse companies.</p>\n<p>The S&amp;P 500 ETF includes stocks from 500 large companies, while the Total Stock Market ETF includes nearly 4,000 stocks from small, midsize, and large corporations. This provides greater diversification and can decrease your risk.</p>\n<p>Another advantage of this fund is that it's designed to follow the market as a whole. Again, the stock market has a strong track record when it comes to recovering from downturns, so by investing in this ETF, it's likely your investments will recover as well.</p>\n<h3>3. Vanguard Growth ETF (VUG)</h3>\n<p>The <b>Vanguard Growth ETF</b> (NYSEMKT:VUG) includes 285 stocks from companies that are expected to grow at a faster-than-average pace.</p>\n<p>This fund includes the fewest holdings of the three ETFs on the list, which does make it slightly riskier. However, many of the biggest stocks in the fund are from behemoth tech corporations like <b>Amazon</b>, <b>Apple</b>, and <b>Microsoft</b> -- companies that are very likely to survive market volatility.</p>\n<p>One of the primary advantages of growth ETFs is that they're designed to earn above-average returns. This particular ETF has earned an average rate of return of around 12% per year since its inception, for example. By comparison, the S&amp;P 500 has historically earned a 10% average annual return, and the Vanguard Total Stock Market ETF has earned an average return of around 9% per year.</p>\n<p>Investing in ETFs can be a fantastic way to build wealth with less effort, and buying during a market downturn can make investing more affordable. While nobody knows for certain whether a market crash is coming, by making a list now of the investments you want to buy, you can snag them at a discount later.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Vanguard ETFs I'm Buying if the Stock Market Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Vanguard ETFs I'm Buying if the Stock Market Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-30 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/29/3-vanguard-etfs-buy-if-the-stock-market-crashes/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nobody knows whether the market will crash. But if it does, I'm stocking up on these investments.\n\nKey Points\n\nThe Vanguard S&P 500 ETF can be a great option for withstanding market volatility.\nThe ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/29/3-vanguard-etfs-buy-if-the-stock-market-crashes/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","IVV":"标普500指数ETF","SPXU":"三倍做空标普500ETF","SSO":"两倍做多标普500ETF","SDS":"两倍做空标普500ETF","VTI":"大盘指数ETF-Vanguard MSCI","UPRO":"三倍做多标普500ETF","OEF":"标普100指数ETF-iShares","OEX":"标普100","VOO":"Vanguard标普500ETF",".SPX":"S&P 500 Index","SH":"标普500反向ETF","VUG":"成长股指数ETF-Vanguard MSCI","SPY":"标普500ETF"},"source_url":"https://www.fool.com/investing/2021/09/29/3-vanguard-etfs-buy-if-the-stock-market-crashes/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2171986054","content_text":"Nobody knows whether the market will crash. But if it does, I'm stocking up on these investments.\n\nKey Points\n\nThe Vanguard S&P 500 ETF can be a great option for withstanding market volatility.\nThe Vanguard Total Stock Market ETF can help reduce your risk.\nThe Vanguard Growth ETF can supercharge your investments.\n\nOver the past year and a half, the stock market has experienced one of the greatest growth streaks in history. The S&P 500 is up nearly 100% since March 2020, and investors have seen their portfolios skyrocket during that time.\nSome experts believe, however, that it's only a matter of time before prices fall. Market downturns may be intimidating, but they're normal. In fact, it's healthy for the market to experience corrections every so often, because stock prices can't continue climbing forever.\nNobody knows for sure whether a crash is on the horizon, or, if it does happen, how significant it will be. However, if the market does take a turn for the worse, there are a few exchange-traded funds (ETFs) I'll be buying.\n\nImage source: Getty Images.\n1. Vanguard S&P 500 ETF (VOO)\nIt may seem counterintuitive to buy when the market is down, but crashes can be a fantastic opportunity to invest when prices are lower. ETFs trade like stocks, so when the market is down, their share prices are typically lower as well.\nOne ETF I'm planning to invest in heavily if the market crashes is the Vanguard S&P 500 ETF (NYSEMKT:VOO). Like its name suggests, this fund tracks the S&P 500 and includes all the stocks within the index itself.\nThe S&P 500 ETF is one of the most dependable investments out there. Historically, the index itself has faced countless crashes and corrections, and it has recovered from each and every one. If the market crashes again, there's a very good chance this ETF will be able to bounce back. And by buying when prices are lower, you'll reap the rewards once the market recovers and prices increase once again.\n2. Vanguard Total Stock Market ETF (VTI)\nThe Vanguard Total Stock Market ETF (NYSEMKT:VTI) is similar to the S&P 500 ETF, but it includes more stocks from more diverse companies.\nThe S&P 500 ETF includes stocks from 500 large companies, while the Total Stock Market ETF includes nearly 4,000 stocks from small, midsize, and large corporations. This provides greater diversification and can decrease your risk.\nAnother advantage of this fund is that it's designed to follow the market as a whole. Again, the stock market has a strong track record when it comes to recovering from downturns, so by investing in this ETF, it's likely your investments will recover as well.\n3. Vanguard Growth ETF (VUG)\nThe Vanguard Growth ETF (NYSEMKT:VUG) includes 285 stocks from companies that are expected to grow at a faster-than-average pace.\nThis fund includes the fewest holdings of the three ETFs on the list, which does make it slightly riskier. However, many of the biggest stocks in the fund are from behemoth tech corporations like Amazon, Apple, and Microsoft -- companies that are very likely to survive market volatility.\nOne of the primary advantages of growth ETFs is that they're designed to earn above-average returns. This particular ETF has earned an average rate of return of around 12% per year since its inception, for example. By comparison, the S&P 500 has historically earned a 10% average annual return, and the Vanguard Total Stock Market ETF has earned an average return of around 9% per year.\nInvesting in ETFs can be a fantastic way to build wealth with less effort, and buying during a market downturn can make investing more affordable. While nobody knows for certain whether a market crash is coming, by making a list now of the investments you want to buy, you can snag them at a discount later.","news_type":1},"isVote":1,"tweetType":1,"viewCount":27,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":814852738,"gmtCreate":1630807916924,"gmtModify":1631883903319,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>哈哈","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>哈哈","text":"$Pfizer(PFE)$哈哈","images":[{"img":"https://static.tigerbbs.com/784dbb8577148be5c1e70e19a5fd4e27","width":"1242","height":"1767"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/814852738","isVote":1,"tweetType":1,"viewCount":74,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":842141818,"gmtCreate":1636158315466,"gmtModify":1636158321613,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>[Cry]&nbsp;","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>[Cry]&nbsp;","text":"$Moderna, Inc.(MRNA)$[Cry]","images":[{"img":"https://static.tigerbbs.com/28973fe24239e54b3a55e59eb3a123d5","width":"1242","height":"1968"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/842141818","isVote":1,"tweetType":1,"viewCount":245,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":855892732,"gmtCreate":1635347484881,"gmtModify":1635347485104,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MU\">$Micron Technology(MU)$</a>[Cool]&nbsp;","listText":"<a href=\"https://laohu8.com/S/MU\">$Micron Technology(MU)$</a>[Cool]&nbsp;","text":"$Micron Technology(MU)$[Cool]","images":[{"img":"https://static.tigerbbs.com/635c04fb6637e04cd821197afbbed19e","width":"1242","height":"1968"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/855892732","isVote":1,"tweetType":1,"viewCount":11,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":822372296,"gmtCreate":1634096739898,"gmtModify":1634096742022,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>[What]&nbsp;","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>[What]&nbsp;","text":"$Pfizer(PFE)$[What]","images":[{"img":"https://static.tigerbbs.com/6cf5f498a2e32fbe664b5e5f6fd6d457","width":"1242","height":"1968"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/822372296","isVote":1,"tweetType":1,"viewCount":58,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":823174054,"gmtCreate":1633608042832,"gmtModify":1633608070077,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>[Cool]&nbsp;","listText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>[Cool]&nbsp;","text":"$Alibaba(BABA)$[Cool]","images":[{"img":"https://static.tigerbbs.com/79af15aca424095a6ecefd0d40e83c56","width":"1242","height":"2208"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/823174054","isVote":1,"tweetType":1,"viewCount":198,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":862164528,"gmtCreate":1632844685353,"gmtModify":1632844685427,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMZN\">$Amazon.com(AMZN)$</a>[Cry]&nbsp;","listText":"<a href=\"https://laohu8.com/S/AMZN\">$Amazon.com(AMZN)$</a>[Cry]&nbsp;","text":"$Amazon.com(AMZN)$[Cry]","images":[{"img":"https://static.tigerbbs.com/119c27235fe70aafde60a72f80f987e6","width":"1242","height":"1968"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/862164528","isVote":1,"tweetType":1,"viewCount":52,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":847642983,"gmtCreate":1636517772550,"gmtModify":1636517772826,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NXPI\">$NXP Semiconductors NV(NXPI)$</a>[Cool]&nbsp;","listText":"<a href=\"https://laohu8.com/S/NXPI\">$NXP Semiconductors NV(NXPI)$</a>[Cool]&nbsp;","text":"$NXP Semiconductors NV(NXPI)$[Cool]","images":[{"img":"https://static.tigerbbs.com/4e62edf73fe39fe5f972b979658eeafd","width":"1125","height":"3507"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847642983","isVote":1,"tweetType":1,"viewCount":606,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":844857544,"gmtCreate":1636418648922,"gmtModify":1636418649186,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Come come up up 🆙&nbsp;","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Come come up up 🆙&nbsp;","text":"$Moderna, Inc.(MRNA)$Come come up up 🆙","images":[{"img":"https://static.tigerbbs.com/c9d64a4e8780c0e5a8ad38a4626fe414","width":"1242","height":"1968"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844857544","isVote":1,"tweetType":1,"viewCount":654,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":842783802,"gmtCreate":1636244608002,"gmtModify":1636244608874,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FB\">$Meta Platforms, Inc.(FB)$</a>[Cool]&nbsp;","listText":"<a href=\"https://laohu8.com/S/FB\">$Meta Platforms, Inc.(FB)$</a>[Cool]&nbsp;","text":"$Meta Platforms, Inc.(FB)$[Cool]","images":[{"img":"https://static.tigerbbs.com/68c32cfcb72ec421c8d35d73b9ec35fa","width":"1125","height":"3670"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842783802","isVote":1,"tweetType":1,"viewCount":536,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":842141777,"gmtCreate":1636158350253,"gmtModify":1636158350477,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>[Spurting]&nbsp;","listText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>[Spurting]&nbsp;","text":"$Alibaba(BABA)$[Spurting]","images":[{"img":"https://static.tigerbbs.com/8a94031a1afcf7cd28d3410d854f4c87","width":"1125","height":"3670"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842141777","isVote":1,"tweetType":1,"viewCount":169,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":840204591,"gmtCreate":1635647046426,"gmtModify":1635647046499,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>[What]&nbsp;","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>[What]&nbsp;","text":"$Apple(AAPL)$[What]","images":[{"img":"https://static.tigerbbs.com/39368fd886145768fbfffa5721905751","width":"1125","height":"3507"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/840204591","isVote":1,"tweetType":1,"viewCount":15,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":857741395,"gmtCreate":1635563534815,"gmtModify":1635563570175,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FB\">$Meta Platforms, Inc.(FB)$</a>[Miser]&nbsp;","listText":"<a href=\"https://laohu8.com/S/FB\">$Meta Platforms, Inc.(FB)$</a>[Miser]&nbsp;","text":"$Meta Platforms, Inc.(FB)$[Miser]","images":[{"img":"https://static.tigerbbs.com/3393e434232fd950886635519c87669a","width":"1242","height":"1968"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/857741395","isVote":1,"tweetType":1,"viewCount":9,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":854423026,"gmtCreate":1635474994276,"gmtModify":1635474994543,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FB\">$Facebook(FB)$</a>[What]&nbsp;","listText":"<a href=\"https://laohu8.com/S/FB\">$Facebook(FB)$</a>[What]&nbsp;","text":"$Facebook(FB)$[What]","images":[{"img":"https://static.tigerbbs.com/5afeb59f2342cfb3cfec136cfef3e0fd","width":"1125","height":"3425"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854423026","isVote":1,"tweetType":1,"viewCount":15,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":829614435,"gmtCreate":1633497587763,"gmtModify":1633497587990,"author":{"id":"3580175323096207","authorId":"3580175323096207","name":"Envyapple","avatar":"https://static.tigerbbs.com/8c4a957e7523570146ea59f23a1d963a","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>[Cry]&nbsp;","listText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>[Cry]&nbsp;","text":"$Alibaba(BABA)$[Cry]","images":[{"img":"https://static.tigerbbs.com/de3b0e83c998916d3112f92ed822c2fe","width":"1242","height":"1968"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/829614435","isVote":1,"tweetType":1,"viewCount":17,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"lives":[]}